Highlights
- 1Cell metabolism · 2020
Publications
Funding
Active
3 grants- MPIR01DK133988-04Them1 Inhibitors for the Management of Non Alcoholic Fatty Liver DiseaseNIDDK · 2023–2028 · via NIH RePORTER
- PIT32DK135449-02Research Training in Gastrointestinal and Hepatic DiseasesNIDDK · 2023–2028 · via NIH RePORTER
- PIR01DK048873-31Lipid Mediated Control Transfer of Acetyl CoA Metabolism in the Pathogenesis of NAFLDNIDDK · 1996–2027 · via NIH RePORTER
Completed grants (14)
- MPIT32DK116970-03Multidisciplinary Research Training in Gastroenterology and HepatologyNational Institute of Diabetes and Digestive and Kidney Diseases · 2019–2025Training
- Co-IR01DK132427-01The role of PKM2 in dietary lipid absorption and fructose-induced obesityNational Institute of Diabetes and Digestive and Kidney Diseases · 2022–2024
- PIR01DK103046-09Them1-Mediated Metabolic Regulation and Pathogenic Role in NAFLDNational Institute of Diabetes and Digestive and Kidney Diseases · 2017–2023· 2 renewals
- PIDFI 221754-01Them1 Inhibitors for the Management of Obesity-Related DisordersDaedalus Fund for Innovation (Weill Cornell) · 2021–2022BioPharma Alliance
- PISRA 200523-01Leveraging Gut Microbial Adaption to Thermal and Nutritional-Stress in the Management of Obesity-Related Metabolic Disorders and Vascular AgingKaohsiung Medical University · 2019–2022Contract
- PIR37DK048873-27Regulation of Hepatic Lipid and Glucose Metabolism by PC-TP/StarD2National Institute of Diabetes and Digestive and Kidney Diseases · 2017–2022· 2 renewals
- PIR01DK056626-23Phospholipid-Mediated Metabolic Control in the Pathogenesis of NAFLDNational Institute of Diabetes and Digestive and Kidney Diseases · 2017–2022· 2 renewals
- KPR03DK117247-01A1Acot9 Promotes LipotoxicityNational Institute of Diabetes and Digestive and Kidney Diseases · 2019–2021
- KPAHA 19POST34380692Muscle-specific metabolic regulation by thioesterase superfamily member 2 (Them2)American Heart Association · 2019–2020
- PISUS 182871-01Sanofi Innovation Awards Program Funding Award AgreementSanofi S.A. · 2017–2020Contract
- PIDFI 180060-01Them1 Inhibitors for the Management of Obesity-Related DisordersDaedalus Fund for Innovation (Weill Cornell) · 2017–2018
- Sub-PINPRP 7-1300-1-241IRE1a and XBP1 Dependent MicroRNAs and Their Role in Hepatic Lipid MetabolismQatar National Research Fund · 2015–2018 · via Weill Cornell Medical College/Qatar
- PIR24DK091211-01Etiology of Cystic Fibrosis-Related Diabetes in a CFTR-knockout FerretNIDDK · 2011–2013 · via NIH RePORTER
Honors & distinctions
- Member · Association of American Physicians · 2020
- Member · American Society for Clinical Investigation · 2003
News mentions
- Protein That Puts the Brakes on Fat Burning Could Be Obesity Drug TargetJune 28, 2021
A protein called Them1 prevents fat burning in cells by blocking access to the fuel source, according to preclinical research by Weill Cornell Medicine, NewYork-Presbyterian and Harvard Medical School/Beth Israel Deaconess Medical Center investigators.
- Two Weill Cornell Medicine Physician-Scientists Inducted into Association of American PhysiciansJuly 1, 2020
Two distinguished Weill Cornell Medicine physician-scientists have been elected to the prestigious Association of American Physicians (AAP).
- Gut Microbiome Controls Blood Glucose Levels Through the LiverFebruary 20, 2020
Gut microbes influence blood glucose levels by acting directly on the liver, not by regulating the energy expenditure of specialized fat tissues, which use glucose as fuel to create heat.
- Dr. Randy Longman Appointed Director of the Jill Roberts Center for Inflammatory Bowel DiseaseOctober 29, 2019
Dr. Randy Longman, an accomplished physician-scientist, has been appointed director of the Jill Roberts Center for Inflammatory Bowel Disease at Weill Cornell Medicine and NewYork-Presbyterian/Weill Cornell Medical Center.
External relationships
Other Interest
Aegerion Pharmaceuticals · American Association for the Study of Liver Diseases Foundation · Beijing Association of Precision Medicine · Esperion Therapeutics · Intercept Pharmaceuticals, INC · PTC Therapeutics · Relburn-Metabolomics, Inc. · Surrozen, Inc.